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Abstract
Ocular involvement in chikungunya virus (CHIKV) infection can be present as mild and
vision-threatening ocular complications with unilateral or bilateral compromise in both
gender and all ages. Precise prevalence and incidence are unknown, but ocular involve‐
ment of CHIKV infection is uncommon. Anterior uveitis is the most common syndromic
manifestation; nevertheless the infection could manifest posterior segment repercussion,
such as retinitis which is the other most usual clinical manifestation. At the beginning of
the systemic disease, main ophthalmologic symptoms are conjunctival injection, retro-oc‐
ular pain, and photophobia. Ocular pathogenesis of CHIKV infection is not totally clari‐
fied; however, findings related to an immune dysregulation and proinflammatory
processes are the most accepted theories. The diagnosis of CHIKV is based on polymer‐
ase chain reaction, virus isolation, or detection of viral antigens which should be used be‐
fore the eighth day of systemic illness. After 8 days, chikungunya serologic tests such as
IgM ELISA/rapid tests or IgG paired must be used. Actual management is focused ac‐
cording to the clinical context of each patient. While in most instances recovery of vision
to normal occurs, CHIKV infection can result in blindness, the visual prognosis depends
on various factors, but the common one is the early onset of corticosteroid treatment.
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1. Introduction
Ocular involvement in chikungunya virus (CHIKV) infection was unheard until the end of
2006 [1]. Since then, it has been demonstrated that CHIKV infection can cause both mild and
vision-threatening ocular complications. Precise prevalence and incidence estimations of
ocular manifestations in CHIKV infection are unknown, further have been reported to be
uncommon [2–4].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
In an attempt to determine the viral causes of anterior uveitis in a South Indian patient
population, Babu et al. realized a retrospective nonrandomized study between January 2009
and July 2012; they found two cases of CHIKV-related anterior uveitis; among 36 patients
included, the two of them had unilateral involvement [5].
The infection has plenty of ocular manifestations as reported in the case reports and case series;
these could be present at the time of systemic illness or after resolution of systemic disease [1,
6, 7] but usually occurs after a latent period of a month to a year, but the presentation time also
depends on the type of clinical presentation. Anterior uveitis and retinitis are the most common
findings; with a typically benign clinical course, it has been reported that anterior uveitis affects
more than 25% of the patients [2, 6, 8]. Posterior segment involvement may manifest as retinitis,
choroiditis, neuroretinitis, and optic neuritis [1, 2, 7–11].
Commonly, in the acute phase of chikungunya fever, patients could manifest photophobia and
retro-orbital pain [6, 12]; other ophthalmic manifestations of chikungunya virus infection
include panuveitis, optic neuritis, keratitis, episcleritis, central retinal artery occlusion,
exudative retinal detachment, lagophthalmos, and VIth nerve palsy [2, 6, 8, 13]; there are a
variety of clinical manifestations that will be completely mentioned in other sections of this
chapter.
Mittal et al. described a case series of 14 patients with confirmed CHIKV infection and optic
neuritis; of them 42% had papillitis; 21% had retrobulbar neuritis; another 21% had optic tract
involvement, and 16% had neuroretinitis [13]. Four years after this publication, Rose et al.
reported an observational study involving 10 patients, who were confirmed cases of infection
with CHIKV with acute optic neuritis. All 10 patients in the study presented with sudden onset
decrease in vision and had a history of fever, joint pain, and skin rash. Among the 10 cases,
30% had bilateral disturbance and 70% had complaints only in one eye. The types of optic
neuritis were unilateral papillitis (40%), bilateral papillitis (30%), retrobulbar neuritis (10%),
perineuritis (10%), and neuroretinitis (10%) [10]. Meanwhile during 2011 a case of bilateral
chikungunya neuroretinitis in a 65-year-old Asian-Indian, who presented with a month-old
history of sudden, painless diminution of vision in both eyes and was treated with oral steroids
and oral acyclovir for 3 weeks, was published, after which partial resolution was noted [14].
Meanwhile, Mahendradas et al. reported a different spectrum of ocular manifestations in nine
patients with a positive serology for CHIKV: 55% had iridocyclitis, 33% had retinitis, and one
patient of nine included had nodular episcleritis [8]. Conjunctivitis also been reported as a
manifestation of CHIKV ocular infection, which looks like another viral infection and resolves
spontaneously [9].
A report of the first known case of bilateral granulomatous panuveitis secondary to chikun‐
gunya fever in the United States, acquired by a US citizen traveling from an endemic region,
was done by Scripsema et al.; they described a case of a 47-year-old woman presented with 10
days of bilateral decreased vision and photophobia with a concurrent febrile illness. Initially,
she responded to corticosteroid treatment but developed recurrent inflammation 3 months
after completing the initial treatment. Immunomodulatory therapy was initiated at the time
of recurrence, and with this therapy alone, her inflammation has been controlled for 6 months.
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In this article, the authors show that according to current reports of chikungunya fever-related
uveitis with posterior inflammation, the distribution of presentation includes papillitis or optic
neuritis (34%), neuroretinitis (12%), retrobulbar optic neuritis (14%), retinitis (11%), panuveitis
(9%), choroiditis (7%), retrochiasmal or optic tract neuritis (7%), exudative retinal detachment
(4%), and perineuritis (2%) [15].
Kalpana et al. presented a case series of 58 patients with Fuchs heterochromic iridocyclitis
(FHI) and found one case caused by CHIKV; nevertheless the authors explain that it is difficult
to speculate the association of FHI and chikungunya virus in this patient [16]. Before this case
series, during 2010 Mahendradas et al. published the first report where the presence of
chikungunya virus RNA has been associated with a case of bilateral Fuchs heterochromic
iridocyclitis, although the authors clear that it is not accurate if the chikungunya virus was the
initiator of the disease or a coincidental finding [17].
Ocular involvement caused by chikungunya virus should be included in the differential
diagnosis, especially in the endemic areas, of any patient presenting with ocular manifestations
and a history of fever, even more when this is accompanied by suggestive symptoms of an
infection caused by CHIKV [18]. This chapter describes the most important aspects of the
ocular compromise caused by CHIKV, items that the clinicians should consider when ap‐
proaching a patient with a suspected ocular involvement by the mentioned virus.
2. Ocular pathogenesis
Ophthalmologic involvement due to chikungunya virus infection is a state that affects plenty
of structures of the eyeball including the eyelids, conjunctiva, cornea, sclera, episclera, iris,
retina, optic nerve, etc. This diversity of ocular findings has been mainly associated with the
most recent outbreaks of the virus because of genomic variations resulting in different virus
strains with changes in activity and virulence. The outbreak of the disease in La Réunion, an
island in Indian Ocean, is related to a different strain of the virus which has been associated
with a higher replication rate than West African and Asian strains of chikungunya virus
according to studies in animals [19, 20]. It is not pretty clear the exact pathogenic mechanism
through chikungunya virus makes its disturbances in different tissues, especially the eye;
however a group of successive steps has been proposed to describe the cycle of infection that
applies for systemic and ocular disease (Figure 1) [19, 21].
The initial response of the body involves an elevation of type I interferon levels and a hyper‐
sensitivity reaction mediated by antibodies against viral antigens causing joint symptoms and
the possible beginning of ocular compromise [21]. The existence of a huge controversy about
the determination of target cells compromised by chikungunya virus has marked the research
pattern in the last years in an attempt to create new therapeutic interventions. Some researches
in recent years have determined that fibroblasts, endothelium and epithelium cells, and
macrophages are susceptible to infection by chikungunya virus, especially by La Réunion
strain, leading to apoptosis in some cases [22]. Different studies made in mice and humans
have found that fibroblasts are the major cell target for chikungunya virus, including those in
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eyeball tissues, something that can be explained by their reticular network formed by gap
junctions making possible dissemination from cell to cell; nevertheless the exact mechanism
has not been described [23, 24].
In the eye, the cornea commitment depends on the infection of epithelial and endothelial cells,
which are the target cells of chikungunya virus at this level. There is evidence about the
potential risk of transmission of chikungunya virus through corneal graft transplantation.
According to Courdec et al., they identified a group of corneal donors who were seropositive
for CHIKV IgM and/or IgG, and their samples showed evidence of the presence of the virus
after the conventional eye bank preservation methods, which were ineffective to inactivate the
virus from the corneal samples, and conclude that CHIKV can be transmitted via ocular route
in humans, coinciding with studies made in immunocompetent mice demonstrating that the
corneal tissue infected with chikungunya virus in replication state that was inoculated onto
scarified cornea leads to viral transmission in the studied mice [24]. This study also determined
that the presence of replication-competent virus in the eye did not correlate with viral detection
in the blood or the presence of antiviral antibodies. Other sites in the eyeball like the scleral
connective tissue, stroma of smooth muscles of ciliary bodies, and stroma of the iris, the
fibroblast is the ideal cell for the virus because of its high rate of replication that leads to a huge
production of infectious viral particles. Besides, there have also been signals of infection
between fibers of ocular muscles [25].
Involvement of the optic nerve is not pretty clear; nevertheless it is presumed that an immune
dysregulation, superantigen induction, hypersensitivity reaction, and molecular mimicry
between stimulating virus-derived antigens and normal or altered host tissue proteins may be
the causes of the optic nerve damage [10, 13, 26, 27].
Figure 1. Systemic and ocular pathogenic process of chikungunya virus infection. Based on Couderc T and Lecuit M.
Chikungunya virus pathogenesis: From bedside to bench. Antiviral Res. 2015;121:120-131.
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There are descriptions about fluctuations in the values of intraocular pressure when inflam‐
matory processes in anterior segment occur. Hypotension may occur when a loss of integrity
of the blood-aqueous barrier exists leading to an increased aqueous humor flow. Episodes of
ocular hypertension happen when inflammation of trabecular system appears, leading to
obstruction of aqueous humor flow [28].
There is a theory that serves as a complement for chikungunya pathogenesis, including the
ocular compromise, and consists of an increased production of chemokines, like interleukin-8
(IL-8) and monocyte chemoattractant protein 1(MCP1), by infected monocyte-derived
macrophages. However, this last theory is just a hypothesis based on studies made using the
Ross River virus, which is a virus that belongs to alphavirus family, as the chikungunya virus;
therefore it can keep some behavior similarities with CHIKV [23, 29]. Primary cultures of B
and T cells, monocytes, and monocyte-derived dendritic cells were found not to be susceptible
to CHIKV infection in vitro [19, 22, 30].
In summary, ocular pathogenesis in context of CHIKV infection is a process that is not totally
clarified, despite the progressively increase in research about this field in recent years;
however, findings related to an immune dysregulation state and proinflammatory processes
are the most accepted theories and could guide the course of ophthalmologic research about
this field in the coming years.
3. Clinical findings
Ophthalmologic manifestations due to chikungunya infection are a set of pathologies that
cause different degrees of damages, involving plenty of structures on anterior and posterior
pole during the course of the systemic disease, even after its resolution with a latent period of
a month to a year [6, 31], and can be present as both mild and vision-threatening ocular
complications with unilateral or bilateral compromise in both gender and all ages [32], being
retinitis and uveitis the most common syndromic manifestations. At the beginning of the
systemic disease, main visible clinical symptoms are conjunctival injection, retro-ocular pain,
and photophobia [2, 12, 33]; meanwhile other existing symptoms like blurred vision, floaters,
epiphora, irritation, and diplopia usually appear after a latent period of a month to a year
(during chronic phase) [16, 32, 34].
The time between beginning of fever and the onset of ophthalmologic symptoms is unknown;
however some retrospective researches in an attempt to determine this interval have shown
that involvement of visual acuity initiates approximately 4 weeks after fever begins, pain and
floaters can be present after 12 weeks, and redness can appear 10–12 weeks after fever onset
[8]; nevertheless these intervals can fluctuate according to the specific affected ocular structure
and the degree of involvement. Also, the small number of patients used by researchers in these
studies makes accurate data on these aspects too difficult to reach, but initial approximations
like this allow the creation of bigger studies that make possible to find high-impact data.
Ocular manifestations of chikungunya virus can keep some similarities with other viruses like
dengue and Zika. Dengue ocular manifestations are uncommon but can be present particularly
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in young adults with a mean age of early 30s and without any sex predilection, debuting when
platelets are at lowest count, especially one week after fever onset [18].The most common
ocular findings due to dengue fever are subconjunctival hemorrhage, dengue maculopathy,
anterior uveitis, vitreitis, retinal pigment epithelium mottling, foveolitis, retinochoroiditis,
choroidal effusion, optic disk swelling, optic neuritis, neuroretinitis, panophthalmitis, retinal
hemorrhages, and oculomotor nerve palsy [31, 32, 34].
Zika ocular manifestations are included in the category of “atypical”; however the ophthal‐
mologic manifestations which have been described in literature until now are the non-
mucopurulent conjunctivitis and the retro-ocular pain. In a Yap island population when an
outbreak of Zika virus was informed, about 55% of cases were reported with the presence of
non-mucopurulent conjunctivitis and 39% of cases with retro-ocular pain; uveitis and different
ocular inflammatory processes were not reported [35]. Differential diagnosis with dengue and
chikungunya viruses should be based in all manifestations and not purely based on ophthal‐
mologic findings [36].
3.1. Anterior uveitis
Anterior uveitis, including granulomatous and non-granulomatous variety, is the main ocular
condition due to infection caused by chikungunya virus [2]. There is no evidence that dem‐
onstrates that uveitis secondary to chikungunya virus has a different behavior than uveitis
caused by other etiologies, particularly those from other arboviruses such as dengue [37]. It is
defined as an inflammation of the uveal tract, specifically the iris and pars plicata of the ciliary
body. The presence of symptoms can be insidious or sudden, taking between a few weeks to
a few months to resolve. Main clinical manifestations include pain, photophobia, conjunctival
injection, hypopyon (the presence of inflammatory cells in anterior chamber and according to
their number represents ocular disease activity), epiphora, and pigmented central globular
keratic precipitates with an infiltrative and dendritic pattern on the surface of the corneal
endothelium in some cases (Figure 2.) [38].
Figure 2. Pigmented keratic precipitates at cornea. Picture took by Diego Zamora-de la Cruz.
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The visual acuity can be affected depending on severity and activity state of the uveitis; miosis
can be present, making a predisposition to formation of posterior synechia, which is the main
complication related to anterior uveitis [12, 39]. Funduscopy is usually normal, but it should
always be realized for excluding anterior uveitis due to an infection by toxoplasma or acute
retinal necrosis in posterior pole. It is possible to develop high intraocular pressure in the
context of an open corneoscleral angle [32]. It is clearly established that chikungunya anterior
uveitis can imitate a herpetic anterior variety [40]. However, we can differentiate both: In the
first one the compromise is more bilateral [41], exists past history of fever with joint pain, have
being in endemic areas [33, 42, 43], and there are positive serologic results [12, 32, 41].
Ocular compromise by CHIKV could manifest also as Fuchs heterochromic iridocyclitis (FHI),
which is a disease of unknown etiology characterized by low-grade intraocular inflammation,
iris heterochromia and/or atrophy, keratic precipitates with stellate morphology with fibrillary
extensions, the absence of synechiae, development of cataract, and in few cases increased
intraocular pressure; however this syndrome has been much more linked to other infections
and noninfectious diseases than chikungunya virus (Figure 3.) [16].
Figure 3. Fuchs heterochromic iridocyclitis: (A) normal eye and (B) affected eye. Taken from Babu K, Adiga M, Gove‐
kar S, Kumar B, and Murthy K. Associations of Fuchs heterochromic iridocyclitis in a South Indian patient population.
Journal of Ophthalmic Inflammation and Infection. 2013; 3(14). Reproduced with permission.
According to case reports, a past history of systemic symptoms of chikungunya was reported
in the previous 1–6 weeks; the affectation by FHI was more unilateral with a mean age of 37.95
± 12.42 years (range from 16 to 68 years), and the most common complaint of patients is blurred
vision. Despite these results, it still remains unclear the exact time of the presence of viral
antigen in the aqueous, so it can be difficult to assume a causal role of chikungunya virus in
FHI cases [16, 17, 44].
3.2. Posterior uveitis
Posterior uveitis is less common than anterior uveitis in the context of infection by chikungu‐
nya virus, and it is defined as inflammation of the choroid and/or retina, vitreous, optic nerve
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head, and retinal vessels. According to the Standardization of Uveitis Nomenclature (SUN)
working group, posterior uveitis includes focal, multifocal, or diffuse choroiditis, chorioreti‐
nitis, retinochoroiditis, retinitis, neuroretinitis, and retinal vasculitis [39, 45, 46]. Clinical signs
might be varied according to the structure involved. Decreased vision, central scotoma,
peripheral field defects, and color vision defect can be present. Symptoms in the anterior
segment like conjunctival injection, pain, and hypopyon are less frequent [32].
3.2.1. Retinitis
Retinitis onset occurs between 2 and 4 weeks after febrile period of systemic disease. According
to some authors, this interval can support the hypothesis that ocular lesions could be an
immune-mediated process rather than a direct viral effect [47]. It can be focal, multifocal, or
diffuse. Patients consult with a history of sudden vision lost without pain. Active lesions are
characterized by retinal whitish opacities, poorly demarcated by surrounding edema [39]. It
is usually accompanied by mild vitreitis, retinal hemorrhages, compromise of retinal vessels,
and the presence of areas of retinal whitening in the posterior pole [48]. Funduscopy allows
visualizing focal and multifocal patches of retinitis macular edema, serous detachment at the
macula, and localized involvement of the retinal vessel [49]. It is described that retinitis caused
by chikungunya fever can simulate herpetic and West Nile virus retinitis; thus the importance
of anamnesis lies in the identification of systemic symptoms of chikungunya infection, making
possible the differentiation to other etiologies [50, 51].
3.2.2. Choroiditis
Choroiditis can be, as retinitis, focal, multifocal, or diffuse. It usually does not produce vitreitis
in the absence of concomitant retinal involvement. Choroiditis active lesion is characterized
by a round yellow nodule in any part of the choroid tissue, especially the iris. Vasculitis
includes a compromise of arteries and veins (periarteritis and periphlebitis), and it is charac‐
terized by a perivascular irregular yellow or white cuff and can be associated with hemor‐
rhages [39].
3.3. Optic neuritis
Optic neuritis is an inflammatory, infectious, or demyelinating process that involves optic
nerve. According to funduscopy, it can be classified as retrobulbar neuritis, papillitis, or
neuroretinitis. There exists another classification based on etiology, which is divided into
demyelinating, parainfectious, infectious, and noninfectious optic neuritis. In the case of optic
neuritis due to chikungunya infection, it belongs to parainfectious class, which occurs after the
viral infection [39]. Optic neuritis is characterized by acute or subacute loss of vision, pain with
ocular movements, and color vision defects. Papillitis is the most often clinical sign according
to observational case series. Patients report the presence of blurred vision after a mean of
11.0±14.0 days of a symptom-free period, and the ocular symptoms had a mean duration of 14
days [10, 13].
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3.4. Corneal involvement
Keratitis and keratouveitis are the main conditions that affect corneal tissue in the context of
chikungunya infection. It is an inflammatory process of the cornea. There is no defined time
between systemic symptoms and the onset of corneal compromise; however there are some
studies which affirm that viral infection at the corneal cell can remain asymptomatic for some
periods of time, approximately 1 month according to case reports [3, 25]. Blurred vision and
ocular irritation are some of the associated symptoms, and involvement of corneal surface can
include bilateral punctate superficial keratitis and stromal immune ring formation with
underlying keratic precipitates which can resolve after 2 weeks of topical corticoid therapy
(Figure 2) [2, 3].
3.5. Episcleritis
Episcleritis is defined as inflammation of the episclera, which is the most external layer of
sclera. It is classified as simple or nodular. Regardless of the cause of the pathology, it has a
pattern to recur in the same eye in posterior episodes [39]. Simple episcleritis is characterized
by localized conjunctival injection with a duration of 12 hours approximately. Nodular
episcleritis is represented by conjunctival injection that becomes bigger progressively with the
presence of painful nodules localized almost all the time at the interpalpebral fissure. Epis‐
cleritis has a benign and self-limited course with a total conservation of vision and an excellent
prognosis [8].
3.6. Panophthalmitis
Panophthalmitis in seropositive chikungunya patients is an unusual manifestation by this
agent. It is characterized by an inflammatory process of all structures in the eye. The only case
report on the literature of this manifestation related to chikungunya was in a middle-aged male
patient who presented with painful progressive proptosis with loss of vision in the left eye
over a period of 6 hours with a history of fever, rash, and severe joint pain in the previous five
days. Moreover, the patient presented at physical examination visual acuity with no light
perception, swelling, and redness of both eyelids, raised temperature over the lids, and
proptosis. Despite panophthalmitis is a very rare manifestation, its rapid fulminating course
and severity of symptoms make this one of the most feared ocular manifestations [52].
4. Ophthalmologic diagnosis
As discussed in the additional chapters, the diagnosis of CHIKV is based on polymerase chain
reaction, virus isolation, or detection of viral antigens which should be used before the eighth
day of systemic illness. After 8 days, chikungunya serologic tests such as IgM ELISA/rapid
tests or IgG paired must be used because the viral load will have decreased [53].
Actually, it has not been possible to find any standard method for ocular CHIKV infection;
however according to some authors, the collection of aqueous humor can be useful for the
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determination of virus [12, 17], as it was previously documented in a patient who underwent
cataract surgery [17]. Despite this report, it is not recommended to take samples of aqueous
or vitreous humor if the illness does not threat the integrity or eye function because of the
possibility to cause a superimposed infection.
Collection of aqueous humor can be made through puncture that is performed before pha‐
coemulsification surgery or by taking aqueous samples in the lens remains collection bag and
supplemented with the implementation of reverse transcription polymerase chain reaction
(RT-PCR) [12, 17].
Mahendradas et al. demonstrated that only the aqueous or vitreous humor and no other tissues
such as the anterior lens capsule can become infected by the virus [17]. It is important to
recognize clinically if the inflammation is related to the virus and latent preconditions as some
other viral infections or systemic diseases that trigger the clinical manifestation.
Other tests could be used such as ELISA, immunochromatographic test, hemagglutination
inhibition, or neutralization techniques, which allow diagnosing indirectly the virus infection
through quantification of the IgM and IgG antibodies in serum; however, these are too much
unspecific [12].
To date, the RT-PCR is considered as the gold standard test to identify the etiologic agent in
ocular tissue involvement because of its high specificity and sensitivity rates. The RT-PCR must
be taken when viremia is active (109–1012 viral copies per ml of blood) [52].
As reported by some authors [12, 17], cataract postoperative state of patients with chikungunya
is similar to patients with chronic uveitis; therefore, it must be considered to continue topical
and systemic steroids in the postoperative period.
The definitive diagnosis has to be made by integrating systemic clinical findings with serologic
test for CHIKV. The differential diagnosis is usually made with anterior/posterior uveitis
caused by herpes simplex virus (HSV) and retinitis due to West Nile virus [12].
The panophthalmitis is a global inflammatory process of the eyeball due to CHIKV which has
been reported in the literature [52], but the association between chikungunya and panoph‐
thalmitis is doubtful and requires further investigation; according to Rajan and colleagues, no
evidence of viral agent was found in the ocular tissue.
It is relevant to say that ocular diagnosis of CHIKV has to be always considered as an exclusion
diagnosis, after probing more common etiologies of clinical manifestation mentioned above.
Fluoroangiography and spectral domain optical coherence tomography (SD-OCT) are
additional tests that can be used for ocular chikungunya infection. The first one can reveal
unspecific findings of neuroretinitis, macular edema, and even serous retinal detachments
associated with chikungunya. The use of these tests is not recommended for diagnosis but to
check evolution of inflammatory process. For instance, in retinitis cases analyzed with
fluoroangiography, hypofluorescent areas in late stages of the study are observed; meanwhile
SD-OCT revealed increased reflectivity in the nerve fiber layer zone which can be associated
with serous retinal detachments (Figure 4). Nevertheless, it is so relevant to remind that the
main goal of these studies is to follow up the patient’s clinical course of the ocular disease [8, 12].
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Figure 4. Retinitis findings in SD-OCT and fluoroangiography. (A) Fundus photograph of the left eye showing conflu‐
ent area of retinal whitening suggestive of retinitis. (B) Fundus fluorescein angiography with early hypofluorescence in
the posterior pole, and (C) late hyperfluorescence in the posterior pole. (D) Spectral domain optical coherence tomog‐
raphy (SD-OCT) revealed an increased reflectivity in the nerve fiber layer zone corresponding to the areas of retinitis
with after shadowing and fluid-filled spaces in the outer retina with serous retinal detachment. (E) Fundus photograph
showing resolving retinitis lesion 2 weeks after initiation of systemic steroid therapy. (F) SD-OCT showing decreased
area of hyperreflectivity in the inner retina with resolving retinal detachment. (G) Fundus photograph after 4 months,
showing complete resolution of retinitis. (H) SD-OCT showing resolution of retinitis with thinning of the inner retinal
layers nasal to the fovea. Taken from Mahendradas P, Avadhani K, Shetty R. Chikungunya and the eye: a review.
Journal of Ophthalmic Inflammation and Infection. 2013; 3(35). Reproduced with permission.




There is no specific antiviral treatment for the CHIKV ocular infection to date. Actual treatment
for ocular manifestations due to this virus is focused on control of symptoms and avoidance
of complications resulting from inflammation of ocular tissues [12].
Systemically, the treatment is based on handling inflammation with corticosteroids and
immunomodulators. The treatment is focused according to the clinical context of each patient.
In a patient with an active viral process and an inflammatory ocular event, other causes of
retinitis, scleritis, and uveitis must be excluded.
Murthy et al. reported a case of bilateral retinitis due to a systemic infection of CHIKV.
Inflammation secondary to HSV was documented, and the treatment was made with intrave‐
nous and oral acyclovir, intravitreal ganciclovir, and oral corticoids and focused on decreasing
the viral copies. The role of acyclovir in treatment against ocular CHIKV should be restricted
to cases where CHIKV and HSV concomitant infection is present or when an inefficient
response to anti-inflammatory therapy exists; however, this is still a controversial fact [46, 47].
As soon as ocular inflammation appears, it is convenient to assess the systemic condition of
the patient, with the purpose of identifying contraindications for systemic steroids use, with
the objectives to reduce eye inflammation and prevent irreversible blindness. Nowadays,
treatment is focused only on treating uveitis complications due to CHIKV [8, 12, 38].
5.1. Local treatment
In all patients who experience active anterior segment inflammation, it is preferred to start
treatment with prednisolone acetate 0.2%, eight times a day, with a reductive dose schedule
every 5 days depending on patient response. It is preferred to add cyclopentolate 1.0% twice
a day or tropicamide with phenylephrine every 8 hours, allowing not only the patient
cycloplegia but also iris mobilization, avoiding the formation of posterior synechiae [41].
Occasionally, patients may experience increased intraocular pressure in the context of uvei‐
tis, which can be controlled by adding a topical treatment with timolol 0.5% twice daily. It is
relevant to remind the mechanism by which the increase of intraocular pressure occurs. High
levels of prostaglandins can increase production of aqueous humor, and the presence of
trabeculitis leads to an obstruction of the aqueous humor flow, increasing intraocular pres‐
sure [41].
It is recommended to use some topical nonsteroidal anti-inflammatory drugs to create synergy
with steroid and reduce rapidly the present symptoms. Some examples can include nepafenac
every 12 hours, bromfenac every 6 hours, or topical ketorolac every 8 hours [41].
5.2. Systemic treatment
Once any contraindication to initiate steroids is excluded, intravenous steroids may be started
if inflammatory events such as optical neuritis or any other threatening visual condition are
documented. In the cases of increased refractory intraocular pressure to topical treatment, it
is recommended to add acetazolamide 250 mg twice daily for three days, taking care of the
renal function [41].
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6. Visual prognosis
While in most instances recovery of vision to normal occurs, CHIKV infection can result in
blindness; especially if it courses in association with optic neuritis or neuroretinitis, patients
may present sudden loss of vision caused by chikungunya fever associated with optic neuritis
[4, 10, 18]; this manifestation of the ocular infection may have a progressive visual loss and
may occur rapidly over several hours or over days [10]. Some authors suggest that visual
prognosis is good with anterior segment involvement, whereas that with posterior segment
involvement (retinochoroiditis) is poor [2, 18, 32, 54], though later certain aspects that greatly
influence the visual forecast will be mentioned.
The majority of patients with retinitis have a good visual outcome over a 10- to 12-week period
[12]. It has been described that alterations like granulomatous and non-granulomatous uveitis,
optic neuritis, and dendritic lesions are common lesions with good visual prognosis, but as
noted above, the prognosis is influenced by several aspects, and this is dependent of each
clinical context [2]. On the other hand, macular ischemia and optic disk changes account for
the poor visual outcome seen in a minority of patients [12, 55].
Unlike previously exposed, Mahesh G et al. reported a case of a 48-year-old female with
bilateral neuroretinitis; the patient received early systemic steroids since she had optic disk
involvement, and visual recovery was very satisfactory [1]. Rapid visual recovery is usually
the norm with immediate administration of systemic steroid therapy [10, 13]. An observational
case series that included 14 patients with clinical features of CHIKV infection and associated
optic neuritis reported complete or partial improvement of vision in 71% of patients with good
response to steroids if given early in the course of illness; in this study, the researchers
presented three patients in whom treatment was initiated 1 month after the onset of visual
symptoms for whom there was no visual improvement [13].
Nonce, Chanana et al. [7] reported a case of a 16-year-old male patient with bilateral macular
choroiditis following chikungunya virus infection that started treatment with oral predniso‐
lone; he showed evidence of resolving choroiditis bilaterally within 6 weeks of treatment, but
the vision did not improve further [7].
In an observational study involving 10 patients, whose cases of infection with CHIKV with
acute optic neuritis were confirmed, the overall prognosis in terms of visual acuity, color vision,
pupillary reaction, and visual field was favorable. They received intravenous methylpredni‐
solone for 3 days, followed by oral prednisolone in a tapering dose; the authors emphasize the
importance of prompt establishment of corticosteroid therapy to lead to rapid recovery of
visual function in patients with acute presentation of optic neuritis, but it has no role when
treatment is initiated at a late stage of the disease [10].
A retrospective study showed 14 consecutive cases who presented to the Vitreo Retina
Department of the Minto Ophthalmic Hospital; of them one patient was positive for IgM
chikungunya; she had bilateral anterior non-granulomatous uveitis and retinitis with optic
nerve involvement in one eye; the patient showed a favorable response to oral prednisolone;
the dose was tapered based on clinical response over a period of 6 weeks improving from an
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average of 2/60 to 6/24 vision [49]. In a similar way, a case series that included nine chikungunya
patients with ocular involvement found a benign course in the cases of iridocyclitis and
episcleritis; they showed complete resolution, with preservation of vision, and patients that
presented with retinitis showed gradual resolution over a period of 6 to 8 weeks with systemic
acyclovir and the corticosteroids [8].
Other less fortunate cases have been reported, in which there is no any treatment that can
improve final visual prognosis, such as one of the patients with acute necrotizing panoph‐
thalmitis; although the CHIKV was not isolated from vitreous tap, chorioretinal biopsy, and
other eviscerated materials, the serological studies were positive with high titer of recent
infection. The case resulted in a painful blind eye, which required evisceration [52].
During April of 2015, Hayek et al. reported the first case of a teen girl with CHIKV-induced
stromal keratouveitis; she had complete resolution of the corneal infiltrate after 2 weeks of
topical corticosteroid treatment [3]. As previously described, the visual prognosis depends on
various factors, but the common one that is found in the scientific literature is the early onset
of corticosteroid treatment. However there is no specific agent that was found effective against
the chikungunya virus. Most of the infected patients with CHIKV are treated symptomatical‐
ly, and it is not completely clear whether any therapy is effective in improving the visual
prognosis [8].
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